Roles of ceramide synthase and ceramide clearence genes in nilotinib-induced cell death in chronic myeloidleukemia cells
| dc.contributor.author | Camgoz, Aylin | |
| dc.contributor.author | Gencer, Emel Basak | |
| dc.contributor.author | Ural, Ali Ugur | |
| dc.contributor.author | Avcu, Ferit | |
| dc.contributor.author | Baran, Yusuf | |
| dc.date.accessioned | 2023-11-18T10:06:47Z | |
| dc.date.available | 2023-11-18T10:06:47Z | |
| dc.date.issued | 2011 | |
| dc.description | Baran, Yusuf/0000-0002-1056-4673 | en_US |
| dc.description.abstract | In this study, we aimed to increase the sensitivity of human K562 and Meg-01 chronic myeloid leukemia (CML) cells to nilotinib by targeting bioactive sphingolipids, in addition to investigating the roles of ceramide metabolizing genes in nilotinib induced apoptosis. Cytotoxic effects of nilotinib, C8:ceramide, glucosyle ceramide synthase (GCS) and sphingosine kinase-1 (SK-1) inhibitors were determined by XTT cell proliferation assay and synergism between the agents was determined by isobologram analysis. Also, quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) results demonstrated that expression levels of longevity assurance (LASS) genes in response to nilotinib were correlated with sensitivity to nilotinib. For the first time, The results of this study showed for the first time that nilotinib induces apoptosis through upregulating ceramide synthase genes and downregulating SK-1 in CML cells in addition to inhibition of BCR/ABL. On the other hand, manipulating bioactive sphingolipids toward generation/accumulation of ceramides increased the apoptotic effects of nilotinib in CML cells. | en_US |
| dc.description.sponsorship | TUBITAK [107S317]; Turkish Academy of Sciences | en_US |
| dc.description.sponsorship | We thank the Biotechnology and Bioengineering Center staff of the Izmir Institute of Technology for their help and technical support. This study was supported by TUBITAK with project number 107S317 to Y.B and by by the Turkish Academy of Sciences, Outstanding Young Investigator Programme to Y.B. | en_US |
| dc.identifier.citation | 16 | |
| dc.identifier.doi | 10.3109/10428194.2011.568653 | |
| dc.identifier.issn | 1042-8194 | |
| dc.identifier.issn | 1029-2403 | |
| dc.identifier.uri | https://doi.org/10.3109/10428194.2011.568653 | |
| dc.identifier.uri | http://standard-demo.gcris.com/handle/123456789/7027 | |
| dc.language.iso | en | en_US |
| dc.publisher | Taylor & Francis Ltd | en_US |
| dc.relation.ispartof | Leukemia & Lymphoma | |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | Chronic myeloid leukemia | en_US |
| dc.subject | nilotinib | en_US |
| dc.subject | ceramide | en_US |
| dc.subject | bioactive sphingolipids | en_US |
| dc.subject | apoptosis | en_US |
| dc.title | Roles of ceramide synthase and ceramide clearence genes in nilotinib-induced cell death in chronic myeloidleukemia cells | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.author.id | Baran, Yusuf/0000-0002-1056-4673 | |
| gdc.bip.impulseclass | C5 | |
| gdc.bip.influenceclass | C5 | |
| gdc.bip.popularityclass | C5 | |
| gdc.description.department | Izmir Institute of Technology İYTE | en_US |
| gdc.description.departmenttemp | [Camgoz, Aylin; Gencer, Emel Basak; Baran, Yusuf] Izmir Inst Technol, Fac Sci, Dept Mol Biol & Genet, TR-35430 Izmir, Turkey; [Ural, Ali Ugur; Avcu, Ferit] Gulhane Mil Med Acad, Sch Med, Dept Hematol, Ankara, Turkey | en_US |
| gdc.description.issue | 8 | en_US |
| gdc.description.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | Q3 | |
| gdc.description.volume | 52 | en_US |
| gdc.description.wosquality | Q3 | |
| gdc.identifier.pmid | 21756066 | |
| gdc.identifier.wos | WOS:000292747300024 | |
| gdc.oaire.accepatencedate | 2011-07-14 | |
| gdc.oaire.accesstype | Bronze | |
| gdc.oaire.diamondjournal | FALSE | |
| gdc.oaire.downloads | 106 | |
| gdc.oaire.impulse | 6 | |
| gdc.oaire.influence | 3.30E-09 | |
| gdc.oaire.influencealt | 17 | |
| gdc.oaire.isgreen | TRUE | |
| gdc.oaire.keywords | Cell Survival | |
| gdc.oaire.keywords | Morpholines | |
| gdc.oaire.keywords | Fusion Proteins, bcr-abl | |
| gdc.oaire.keywords | Gene Expression | |
| gdc.oaire.keywords | Antineoplastic Agents | |
| gdc.oaire.keywords | Apoptosis | |
| gdc.oaire.keywords | Ceramides | |
| gdc.oaire.keywords | Cell Line, Tumor | |
| gdc.oaire.keywords | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | |
| gdc.oaire.keywords | Humans | |
| gdc.oaire.keywords | Cell Proliferation | |
| gdc.oaire.keywords | Membrane Potential, Mitochondrial | |
| gdc.oaire.keywords | Dose-Response Relationship, Drug | |
| gdc.oaire.keywords | Caspase 3 | |
| gdc.oaire.keywords | Reverse Transcriptase Polymerase Chain Reaction | |
| gdc.oaire.keywords | Drug Synergism | |
| gdc.oaire.keywords | Protein-Tyrosine Kinases | |
| gdc.oaire.keywords | Nilotinib | |
| gdc.oaire.keywords | Phosphotransferases (Alcohol Group Acceptor) | |
| gdc.oaire.keywords | Pyrimidines | |
| gdc.oaire.keywords | Glucosyltransferases | |
| gdc.oaire.keywords | Bioactive sphingolipids | |
| gdc.oaire.keywords | K562 Cells | |
| gdc.oaire.magid | 2107121421 | |
| gdc.oaire.popularity | 3.93E-09 | |
| gdc.oaire.popularityalt | 1.9421589 | |
| gdc.oaire.publicfunded | FALSE | |
| gdc.oaire.relevantdates | created:2011-07-14 | |
| gdc.oaire.relevantdates | published-online:2011-07-14 | |
| gdc.oaire.relevantdates | published-print:2011-08-01 | |
| gdc.oaire.relevantdates | issued:2011-01-01 | |
| gdc.oaire.sciencefields | 0301 basic medicine | |
| gdc.oaire.sciencefields | 03022001 Oncology/Infectious causes of cancer | |
| gdc.oaire.sciencefields | 03 medical and health sciences | |
| gdc.oaire.sciencefields | 0302 clinical medicine | |
| gdc.oaire.sciencefields | 030104 developmental biology | |
| gdc.oaire.sciencefields | 030220 oncology & carcinogenesis | |
| gdc.oaire.views | 83 | |
| gdc.opencitations.count | 17 | |
| gdc.plumx.crossrefcites | 11 | |
| gdc.plumx.mendeley | 7 | |
| gdc.plumx.pubmedcites | 9 | |
| gdc.plumx.scopuscites | 18 | |
| gdc.sobiad.citedbycount | 0 | |
| gdc.wos.citedbycount | 16 | |
| relation.isAuthorOfPublication | 284ecb77-30bf-4d4d-a1b9-c35c6e2c8434 | |
| relation.isAuthorOfPublication.latestForDiscovery | 284ecb77-30bf-4d4d-a1b9-c35c6e2c8434 |
